193 related articles for article (PubMed ID: 17149595)
1. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
Merchant MS; Melchionda F; Sinha M; Khanna C; Helman L; Mackall CL
Cancer Immunol Immunother; 2007 Jul; 56(7):1037-46. PubMed ID: 17149595
[TBL] [Abstract][Full Text] [Related]
2. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
3. Do Mesenchymal Stromal Cells Influence Microscopic Residual or Metastatic Osteosarcoma in a Murine Model?
Aanstoos ME; Regan DP; Rose RJ; Chubb LS; Ehrhart NP
Clin Orthop Relat Res; 2016 Mar; 474(3):707-15. PubMed ID: 26018200
[TBL] [Abstract][Full Text] [Related]
4. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
Terabe M; Khanna C; Bose S; Melchionda F; Mendoza A; Mackall CL; Helman LJ; Berzofsky JA
Cancer Res; 2006 Apr; 66(7):3869-75. PubMed ID: 16585215
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
6. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Hennessy M; Wahba A; Felix K; Cabrera M; Segura MG; Kundra V; Ravoori MK; Stewart J; Kleinerman ES; Jensen VB; Gopalakrishnan V; Pena R; Quach P; Kim G; Kivimäe S; Madakamutil L; Overwijk WW; Zalevsky J; Gordon N
Int J Cancer; 2021 Apr; 148(8):1928-1937. PubMed ID: 33152115
[TBL] [Abstract][Full Text] [Related]
7. Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
Khanna C; Khan J; Nguyen P; Prehn J; Caylor J; Yeung C; Trepel J; Meltzer P; Helman L
Cancer Res; 2001 May; 61(9):3750-9. PubMed ID: 11325848
[TBL] [Abstract][Full Text] [Related]
8. Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model of Metastasis: A Mouse Osteosarcoma Model.
Maloney C; Edelman MC; Kallis MP; Soffer SZ; Symons M; Steinberg BM
Clin Orthop Relat Res; 2018 Jul; 476(7):1514-1522. PubMed ID: 29601385
[TBL] [Abstract][Full Text] [Related]
9. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
10. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer.
Kundu N; Beaty TL; Jackson MJ; Fulton AM
J Natl Cancer Inst; 1996 Apr; 88(8):536-41. PubMed ID: 8606382
[TBL] [Abstract][Full Text] [Related]
11. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.
Bidwell BN; Slaney CY; Withana NP; Forster S; Cao Y; Loi S; Andrews D; Mikeska T; Mangan NE; Samarajiwa SA; de Weerd NA; Gould J; Argani P; Möller A; Smyth MJ; Anderson RL; Hertzog PJ; Parker BS
Nat Med; 2012 Aug; 18(8):1224-31. PubMed ID: 22820642
[TBL] [Abstract][Full Text] [Related]
12. Potential of human γδ T cells for immunotherapy of osteosarcoma.
Li Z
Mol Biol Rep; 2013 Jan; 40(1):427-37. PubMed ID: 23065272
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A; Gambera S; Leo A; García-Castro J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
[TBL] [Abstract][Full Text] [Related]
14. Positron Emission Tomography Detects
Butch ER; Mead PE; Amador Diaz V; Tillman H; Stewart E; Mishra JK; Kim J; Bahrami A; Dearling JLJ; Packard AB; Stoddard SV; Vāvere AL; Han Y; Shulkin BL; Snyder SE
Cancer Res; 2019 Jun; 79(12):3112-3124. PubMed ID: 31015228
[TBL] [Abstract][Full Text] [Related]
15. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
[TBL] [Abstract][Full Text] [Related]
16. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
17. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
[TBL] [Abstract][Full Text] [Related]
18. Foscan and foslip based photodynamic therapy in osteosarcoma in vitro and in intratibial mouse models.
Meier D; Botter SM; Campanile C; Robl B; Gräfe S; Pellegrini G; Born W; Fuchs B
Int J Cancer; 2017 Apr; 140(7):1680-1692. PubMed ID: 27943293
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
20. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
Gordon N; Kleinerman ES
Cancer Treat Res; 2009; 152():497-508. PubMed ID: 20213411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
